Homocysteine rapidly increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells

Thrombosis and Haemostasis

Volumn 94, Issue 6, 2005, Pages 1285-1293

  Doronzo, Gabriella ^a   Russo, Isabella ^a   Mattiello, Luigi ^a   Trovati, Mariella ^a   Anfossi, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Homocysteine; Matrix metalloproteinases; Mitogen Activated Protein Kinase; Phosphatidylinositol 3 kinase; Vascular smooth muscle cells

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; GELATIN; GELATINASE A; HOMOCYSTEINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL CULTURE; CELL LYSATE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SUPERNATANT; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AORTA; CELL MOVEMENT; CELLS, CULTURED; CHROMONES; DACTINOMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HOMOCYSTEINE; HUMANS; MATRIX METALLOPROTEINASE 2; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN SYNTHESIS INHIBITORS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 29244484401     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-04-0221     Document Type: Article

References (50)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969; 56: 111-28.
2. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
3. Christen WG, Ridker PM. Blood levels of homocysteine and atherosclerotic vascular disease. Curr Atheroscler Rep 2000; 2: 194-9.
4. Van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost 2000; 26: 281-9
5. Durand P, Prost M, Loreau N et al. Impaired homocysteine metabolism and atherothrombotic disease. Lab Invest 2001; 81: 645-72.
6. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Brit Med J 2002; 325: 1202-6
7. Wood JL, Graham A. Structural requirements for oxidation of low density lipoprotein by thiols. FEBS Lett 1995; 366: 75-80.
8. Loscalzo J. The oxidant stress of hyperhomocist(e)inemia. J Clin Invest 1996; 98: 5-7.
9. Mujumdar VS, Aru GM, Tyagi SC. Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem 2001; 82: 491-500.
10. Heydrick SJ, Weiss N, Thomas SR et al. L-homocysteine and L-homocistine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells. Free Rad Biol Med 2004; 36: 632-40.
11. Bellamy MF, McDowell IF, Ramsey MW et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation 1998; 98: 1848-52.
12. Dalal S, Parkin SM, Homer-Vanniasinkam S et al. Effect of homocysteine on cytokine production by human endothelial cells and monocytes. Ann Clin Biochem 2003; 40: 534-41.
13. Dalton ML, Gadson PF Jr, Wrenn RW et al. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997; 11: 703-11.
14. Hansrani M, Gillespie JI, Stansby G. Homocysteine in myointimal hyperplasia. Eur J Vasc Endovasc Surg 2002; 23: 3-10.
15. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
16. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function and biochemistry. Circ Res 2003; 92: 827-39.
17. Dollery CM, Mc Ewan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8.
18. Galis ZS, Muszynski M, Sukhova GK et al. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci 1995; 748: 501-7.
19. Jones CB, Sane DC, Herrington D. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59: 812-23.
20. Freestone T, Turner RJ, CoadyA et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995; 15: 1145-51.
21. Kuzuya M, Iguchi A. Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 2003; 10: 275-83.
22. Smeglin A, Frishman WH. Elastinolytic matrix metalloproteinases and their inhibitors as therapeutic targets in atherosclerotic plaque instability. Cardiol Rev 2004; 12: 141-50.
23. Patterson ML, Atkinson SJ, Knauper V et al. Specific collagenolysis by gelatinase A, MMP-2, is determined by the hemopexin domain and not the fibronectin-like domain. FEBS Lett 2001; 503: 158-62.
24. Galis ZS, Sukhova GK, Lark MW et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503.
25. Brown DL, Hibbs MS, Kearney M et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125-31.
26. Li Z, Li L, Zielke HR et al. Increased expression of 72 kD type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996; 148: 121-8.
27. Galis ZS, Muszynski M, Sukhova GK et al. Cytokine-stimulated human vascular smooth-muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181-9.
28. Whatling C, McPheat W, Hurt-Comejo E. Matrix management. Assigning different roles for MMP-2 and MMP-9 in vascular remodelling. Arterioscler Thromb Vasc Biol 2004; 24: 10-11.
29. Sawicki G, Salas E, Murat J et al. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 616-9.
30. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999; 85: 906-11.
31. Cheung P-Y, Sawicki G, Wozniak M et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 101: 1833-9.
32. Bescond A, Augier T, Chareyre C et al. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 1999; 263: 498-503.
33. Chavarria T, Rodriguez-Nieto S, Sanchez-Jimenez F et al. Homocysteine is a potent inhibitor of human tumor cell gelatinases. Biochem Biophys Res Commun 2003; 303: 572-5.
34. Tyagi SC, Smiley LM, Mujumdar VS et al. Reduction-oxidation (Redox) and vascular tissue levels of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodelling and vascular tone. Mol Cell Biochem 1998; 181: 107-16.
35. Chaussalet M, Lamy E, Foucault-Bertaud A et al. Homocysteine modulates the proteolytic potential of human vascular endothelial cells. Biochem Biophys Res Commun 2004; 316: 170-6.
36. Kurata H, Thant AA, Matsuo S et al. Constitutive activation of MAP kinase kinase (MEK1) is critical and sufficient for the activation of MMP-2. Exp Cell Res 2000; 254: 180-8.
37. Brown JC, Rosenquist TH, Monaghan DT. ERK2 activation by homocysteine in vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 251: 669-76.
38. Zhange D, Bar-Eli M, Meloche S et al. Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor. J Biol Chem 2004; 279: 19683-90.
39. Scott-Burden T, Resink TJ, Hahn AWA et al. Induction of growth-related metabolism in human vascular muscle cells by low density lipoprotein. J Biol Chem 1989; 264: 12582-9.
40. Trovati M, Massucco P, Mattiello L et al. Insulin increases cyclic nucleotide content in human vascular smooth muscle cells: a mechanism potentially involved in insulin-induced modulation of vascular tone. Diabetologia 1995; 38: 936-41.
41. Shastry S, Tyagi SC. Homocysteine induces metalloproteinase and shedding of b-1 integrin in microvessel endothelial cells. J Cell Biochem 2004; 93: 207-13.
42. Holven KB, Halvorsen B, Schulz H et al. Expression of matrix metalloproteinase-9 in mononuclear cells of hyperhomocysteinaemic subjects. Eur J Clin Invest 2003; 33: 555-60.
43. Lee H-Y, Chae I-H, Kim H-S et al. Differential effects of homocysteine on porcine endothelial and vascular smooth muscle cells. J Cardiovasc Pharmacol 2002; 39: 643-51.
44. Stanley HJ, Weiss N, Shane TR et al. L-homocysteine and L-homocystine stereospecifically induce endothelial nitric oxide synthase-dependent lipid peroxidation in endothelial cells. Free Rad Biol Med 2004; 36: 632-40.
45. Ingram AJ, Krepinski JC, James L et al. Activation of mesangial cell MAPK in response to homocysteine. Kidney Int 2004; 66: 733-45.
46. Zhang HS, Cao EH, Qin JF. Homocysteine induces cell cycle G1 arrest in endothelial cells through the PI3K/Akt/FOXO signalling pathway. Pharmacology 2005; 74: 57-64.
47. Rocic P, Govindarajan G, Sabri A et al. A role for PYK2 in regulation of ERK1/2 MAP kinase and PI 3-kinase by ANG II in vascular smooth muscle cells. Am J Physiol Cell Physiol 2001; 280: C90-C99.
48. Pauly RR, Passaniti A, Bilato C et al. Migration of cultured smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994; 75: 41-54.
49. Domanovits H, Schillinger M, Mullner M et al. Acute phase reactant in patients with abdominal aortic aneurysm. Atherosclerosis 2002; 163: 297-302.
50. Warsi AA, Davies B, Morris-Stiff G et al. Abdominal aortic aneurysm and its correlation to plasma homocysteine, and vitamins. Eur J Vasc Endovasc Surg 2004; 27: 75-9.